Cover Image
Market Research Report

Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026

Published by KuicK Research Product code 923628
Published Content info 510 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026
Published: February 3, 2020 Content info: 510 Pages
Description

"Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026" Report Highlights:

  • Global Bispecific Antibody Market Opportunity: > US$ 10 Billion
  • Global Bispecific Antibody Market Growth: 118% CAGR (2015 -2019)
  • Global Bispecific Antibody Market Growth In 2019: 280% (> US$ 1.5 Billion)
  • Global Bispecific Antibody Pipeline: 333 Drug
  • Commercially Available Bispecific Antibodies: 2 (Blincyto & Hemlibra)
  • Hemlibra Sales & Market Share 2019: > US$ 1.4 Billion & > 80%

“Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026” provides comprehensive insight on clinical and non-clinical factors that are driving the global bispecific antibodies market and its impact on the global pharmaceutical market landscape. The report has been prepared in a view to deeply profile the current market trends along with the sales insight on two (Blincyto & Hemlibra) commercially available bispecific antibodies with their regional level revenue, market share and the clinical profile.

"Since Commercially Launch In 2015, The Global Bispecific Antibody Market Has Witnessed Growth of 118% CAGR Till 2019"

The availability of the bispecific antibodies in the market and the revenue generated by the drugs in short span of four years (since commercialization in 2015) clearly depicts the current dominant trends followed by its characterization as a next generation of antibody therapy. The number of the investigational agents under preclinical and clinical trials all around the globe adds as a major key component for the establishment of the antibody therapy as a one stop treatment for all the disease.

Pharmaceutical companies involved in the development of these promising bispecific antibodies molecules strongly believe that their products are superior to first generation nonspecific antibody products. No doubt they are adamant to their viewpoint that bispecific antibodies will be more potent against disease targets, which includes combating more than one aspect of the disease simultaneously, better and cheaper production with least side effects. The molecules are also said to have the potential of dealing with multiple disease with a single agent making them more important.

“Structural Diversity Among The Antibodies Are Opening A Wide Plethora For The Novel Bispecific Antibody Agents, And Thus Providing A Great Opportunity For Establishing A Superior Market In The Future.”

Bispecific antibodies are not only being developed for the oncological use but also the non oncological which includes rejection of organ transplants, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, allergies and ophthalmic problems making their usage area wide enough to make ample of monetary gains in the near future. Their vitality if approved can also make them a great tool in the diagnostics tests detect and monitor infectious agents like HIV, the cause of AIDS, or the influenza virus causing pandemic flu and for identifying diseases released by biological weapons such as smallpox and anthrax. In addition, monoclonal antibodies have also helped in checks for salmonella and bacteria that cause food poisoning. The global opportunity value of the bispecific antibody market is estimated to be approximately US$ 10 billion per year, which is expected to be achieved in next five year timeframe.

Table of Contents

Table of Contents

1. Introduction to Bispecific Monoclonal Antibody

  • 1.1. Overview of Monoclonal Antibody
  • 1.2. Overview of Bispecific Monoclonal Antibody
  • 1.3. Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies

2. The Engineering & Development of Bispecific Antibodies

  • 2.1. Bispecific Antibodies Similar to IgG
    • 2.1.1. Quadroma (Hybrid Hydromas) Approach
    • 2.1.2. “Knobs Into Holes” Approach
    • 2.1.3. CrossMab Approach
    • 2.1.4. Dual-Variable-Domain Immunoglobulin Approach
  • 2.2. Small Bispecific Antibodies
    • 2.2.1. Bispecific Diabodies
    • 2.2.2. Bispecific T-Cell Engager Antibodies (BiTEs)

3. Mechanism Of Action Of Bispecific Antibody

  • 3.1. Trifunctional Antibody: Catumaxomab (Removab®)
  • 3.2. Blinatumomab

4. Applications of Bispecific Antibodies in Diagnostic & Treatment

  • 4.1. BsMAb for Diagnosis of Bacterial & Viral Infectious Diseases
  • 4.2. BsMAb for Cancer Diagnostic
  • 4.3. BsAbs Blocking Signaling Pathways
  • 4.4. BsAbs Targeting Tumor Angiogenesis
  • 4.5. Specific Delivery of Effector Compounds to Targets
  • 4.6. Bispecific Antibodies & Gene Therapy

5. Global Bispecific Antibody Market Outlook

  • 5.1. Current Market Scenario
  • 5.2. Availability of Bispecific Antibodies
    • 5.2.1. Catumaxomab (Removab)
    • 5.2.2. Blinatumomab
    • 5.2.3. Emicizumab
    • 5.2.4. Duligotumab
    • 5.2.5. SAR 156597

6. Approved Bispecific Antibody Dosage & Price Analysis

  • 6.1. Blincyto
  • 6.2. Hemlibra

7. Approved Bispecific Antibody Sales Analysis

  • 7.1. Blincyto
  • 7.2. Hemlibra

8. Global Bispecific Antibodies Clinical Pipeline Overview

  • 8.1. By Phase
  • 8.2. By Country/Region
  • 8.3. By Company
  • 8.4. By Indication
  • 8.5. Orphan Designated Bispecific Antibodies

9. Global Bispecific Antibodies Clinical Pipeline By Company, Indication & Phase

  • 9.1. Research
  • 9.2. Preclinical
  • 9.3. Phase-I
  • 9.4. Phase-I/II
  • 9.5. Phase-II
  • 9.6. Phase-II/III
  • 9.7. Phase-III

10. Marketed Bispecific Antibodies Clinical Insight

  • 10.1. Blinatumomab - Amgen
  • 10.2. Emicizumab - Chugai Pharmaceutical

11. Global Bispecific Antibody Market Dynamics

  • 11.1. Favorable Market Parameters
  • 11.2. Commercialization Challenges

12. Global Bispecific Antibody Market Future Prospects

13. Competitive Landscape

  • 13.1. Ablynx
  • 13.2. Adimab
  • 13.3. Affimed Therapeutics
  • 13.4. Amgen
  • 13.5. AstraZeneca (MedImmune)
  • 13.6. Chugai Pharmaceutical
  • 13.7. Eli Lilly
  • 13.8. EMD Serono
  • 13.9. Emergent BioSolutions
  • 13.10. Genentech
  • 13.11. Genmab
  • 13.12. Immunomedics
  • 13.13. Jounce Therapeutics
  • 13.14. MacroGenics
  • 13.15. Merus
  • 13.16. Neovii Biotech
  • 13.17. NovImmune SA
  • 13.18. OncoMed Pharmaceuticals
  • 13.19. Pieris
  • 13.20. Regeneron Pharmaceuticals
  • 13.21. Roche
  • 13.22. Sanofi

List of Figures

  • Figure 1-1: Advantages of Bispecific Antibodies
  • Figure 2-1: Types of Approaches to Form IgG like Bispecific Antibodies
  • Figure 2-2: Method of Formation of Hybrid Hybridoma
  • Figure 2-3: Limitations of Hybrid Hybridoma
  • Figure 2-4: Steps involved in “Knobs into Holes” Approach
  • Figure 2-5: Three different CrossMabs are Obtained by Three Different Modifications
  • Figure 2-6: Method for formation of Dual-Variable-Domain Immunoglobulin
  • Figure 2-7: Advantages of Dual Variable Domain Immunoglobulin approach
  • Figure 2-8: Types of Bispecific Antibodies
  • Figure 3-1: Mechanism of Action of Bispecific Monoclonal Antibody
  • Figure 3-2: Mechanism of Action of Catumaxomab
  • Figure 3-3: Mechanism of Action of Blinatumomab
  • Figure 4-1: Applications of Bispecific Antibodies
  • Figure 5-1: Global - Bispecific Antibody Market Size (US$ Million), 2015 - 2019
  • Figure 5-2: US v/s ROW - Bispecific Antibody Market Share (%) , 2018
  • Figure 5-3: US v/s ROW - Bispecific Antibody Market Share (%) , 2019
  • Figure 5-4: Global - Bispecific Antibody Market Size (US$ Million) by Products (Blincyto & Hemlibra) , 2018 & 2019
  • Figure 5-5: Global - Bispecific Antibody Market Share(%) by Products (Blincyto & Hemlibra) , 2018
  • Figure 5-6: Global - Bispecific Antibody Market Share(%) by Products (Blincyto & Hemlibra) , 2019
  • Figure 5-7: Global - Bispecific Antibody Quarterly Sales (US$ Million), by Products (Blincyto & Hemlibra), 2019
  • Figure 6-1: Blincyto - Recommended Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL, December'2019
  • Figure 6-2: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days) , December'2019
  • Figure 6-3: Blincyto - Cost of Single Cycle & Full Treatment Cost of MRD+ B-Cell Precursor ALL (US$), December'2019
  • Figure 6-4: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL, December'2019
  • Figure 6-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks), December'2019
  • Figure 6-6: Blincyto - Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), December'2019
  • Figure 6-7: Blincyto - Cost of Different Treatment Phases & Full Treatment Cost for Relapsed B-Cell Precursor ALL (US$), December'2019
  • Figure 6-8: Hemlibra - Cost for Single Unit of 30mcg & 150mcg Subcutaneous Injection (US$), December'2019
  • Figure 6-9: Hemlibra - Recommended Loading & Maintenance Dose for Treatment of Hemophilia (mg/Kg/Week), December'2019
  • Figure 6-10: Hemlibra - Average Monthly & Annual Cost for Treatment of Hemophilia A (US$), December'2019
  • Figure 7-1: Blincyto - Sales Value (US$ Million), 2015 - 2019
  • Figure 7-2: US - Blincyto Sales Value (US$ Million), 2016 - 2019
  • Figure 7-3: Global ( Ex USA) - Blincyto Sales Value (US$ Million), 2016 - 2019
  • Figure 7-4: Blincyto - Quarterly Sales Value (US$ Million), 2018
  • Figure 7-5: Blincyto - Quarterly Sales Value (US$ Million), 2019
  • Figure 7-6: Blincyto - US v/s Rest of World Share in Sales Value (%), 2018
  • Figure 7-7: Blincyto - US v/s Rest of World Share in Sales Value (%), 2019
  • Figure 7-8: Hemlibra - Sales Value by Countries (US$ Million), 2019
  • Figure 7-9: Hemlibra - Sales Value by Countries (US$ Million), 2018
  • Figure 7-10: Hemlibra - Sales Value Share by Countries (%), 2018
  • Figure 7-11: Global - Hemlibra Quarterly Sales Value (US$ Million), 2018
  • Figure 7-12: Global - Hemlibra Half Yearly Sales Value (US$ Million), 2018 & 2019
  • Figure 7-13: Hemlibra - Half Year Sales Value by Countries (US$ Million), 2018 & 2019
  • Figure 7-14: Hemlibra - Quarterly Sales Value (US$ Million), 2019
  • Figure 7-15: Hemlibra - 9 Months Sales Value by Countries (US$ Million), 2019
  • Figure 7-16: Hemlibra - 9 Month Sales Value Share by countries (%), 2019
  • Figure 8-1: Global - Bispecific Antibodies Clinical Pipeline by Phase (%), 2020 till 2026
  • Figure 8-2: Global - Bispecific Antibodies Clinical Pipeline by Phase (Numbers), 2020 till 2026
  • Figure 8-3: Global - Bispecific Antibodies in Clinical Pipeline by Country (Numbers), 2020 till 2026
  • Figure 8-4: Global - Bispecific Antibodies in Clinical Pipeline by Company (Numbers), 2020 till 2026
  • Figure 8-5: Global - Bispecific Antibodies in Clinical Pipeline by Indication (Numbers), 2020 till 2026
  • Figure 8-6: Global - Bispecific Antibodies in Clinical Pipeline by Orphan Status (Numbers), 2020 till 2026
  • Figure 11-1: Favorable Market Parameters Global Bispecific Antibody Market
  • Figure 11-2: Commercialization Challenges for Bispecific Antibody
  • Figure 12-1: Global - Bispecific Antibody Market Opportunity Assessment (US$ Billion), 2020 - 2026
  • Figure 13-1: Ablynx - Clinical Pipeline
  • Figure 13-2: Affimed Therapeutics - Clinical Pipeline
  • Figure 13-3: Amgen - Clinical Pipeline
  • Figure 13-4: EMD Serono - Clinical Pipeline
  • Figure 13-5: Emergent Bioscience - Clinical Pipeline
  • Figure 13-6: Genmab - Clinical Pipeline
  • Figure 13-7: Jounce Therapeutics - Clinical Pipeline
  • Figure 13-8: MacroGenics - Clinical Pipeline
  • Figure 13-9: Merus - Clinical Pipeline
  • Figure 13-10: Novimmune - Clinical Pipeline
  • Figure 13-11: OncoMed - Clinical Pipeline
  • Figure 13-12: Pieris Pharmaceuticals - Clinical Pipeline
  • Figure 13-13: Roche - Clinical Pipeline

List of Tables

  • Table 2-1: List of Bispecific Antibodies Formed by Hybrid Hybridoma Method
  • Table 2-2: List of Bispecific Antibodies Formed by DART
  • Table 2-3: List of Bispecific Antibodies Formed by BiTE Method
  • Table 2-4: List of Other BiTEs
  • Table 4-1: Bispecific Antibodies Targeting Cancer
Back to Top